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Abstract 11 
 12 
Pharmacological modelling of anti-parasitic treatment based on a drug’s pharmacokinetic and 13 
pharmacodynamic properties plays an increasingly important role in identifying optimal drug 14 
dosing regimens and predicting their potential impact in control and elimination programmes. 15 
Conventional modelling of treatment relies on methods that do not distinguish between 16 
parasites being in different developmental stages. This is problematic for malaria parasites as 17 
their sensitivity to drugs varies substantially during their 48-hour developmental cycle. We 18 
investigated four drug types (short/long half-lives with/without stage specific killing) to 19 
quantify the accuracy of the standard methodology. The treatment dynamics of three drug 20 
types were well characterised with standard modelling. The exception were short half-life 21 
drugs with stage specific killing (i.e. artemisinins) because, depending on time of treatment, 22 
parasites might be in highly drug-sensitive stages or in much less sensitive stages. We 23 
describe how to bring such drugs into pharmacological modelling by including additional 24 
variation into the drugs maximal killing rate. Finally, we show that artemisinin kill rates may 25 
have been substantially over-estimated in previous modelling studies because (i) the parasite 26 
reduction ratio (PRR) (generally estimated as 104) is based on observed changes in 27 
circulating parasite number which  generally over-estimates the ‘true’ PRR which should 28 
include both circulating and sequestered parasites, and (ii) the third dose of artemisinin at 48 29 
hours targets exactly those stages initially hit at time zero, so it is incorrect to extrapolate the 30 
PRR measured over 48 hours to predict the impact of doses at times 48 hours and later. 31 
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Introduction 32 
 33 
Identifying optimal deployment policies and improved drug stewardship (for example 34 
suppression of monotherapies and detection of counterfeit drugs) have become major public 35 
health objectives designed to minimise the onset of resistance of the currently recommended 36 
first-line drugs for uncomplicated malaria, i.e. the artemisinin-based combination therapies 37 
(ACTs). One method to identify best practice for their deployment is by pharmacological 38 
modelling of drug action. This has been widely used in other infectious diseases, notably 39 
bacteria (recently reviewed in (1)). Its application to malaria treatment is now being strongly 40 
recommended to optimise deployment practices (2, 3) and the World Health Organization 41 
(WHO) has recommended the development of models to improve the understanding of 42 
antimalarial drug resistance and management (4). Recent examples of pharmacological 43 
modelling can be found elsewhere (5-17), although a less mechanistic approach can also be 44 
employed by fitting curves to observed clinical data (e.g. (18)). Pharmacological models have 45 
a potentially huge impact in contributing to the rational design and deployment of drug 46 
therapies that can potentially save several million lives annually.  47 
 48 
The conventional in silico method of predicting therapeutic outcome of malaria treatment is 49 
to track the number of parasites following drug treatment using ordinary differential 50 
equations (ODEs) (e.g. (19) and discussion of Equation 1 below). Some antimalarial drugs 51 
can act against liver stages and/or gametocytes but it is the asexual blood stages (rings, 52 
trophozoites, schizonts and merozoites) in human red blood cells (RBCs) that cause 53 
symptoms. In this work, we focus exclusively on modelling drug action against these asexual 54 
blood stages. This approach has one major inherent drawback when applied to malaria: it 55 
assumes the malaria parasites within a patient are entirely homogenous, i.e. that all parasites 56 
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are in identical states so that, given a certain drug concentration, all parasites are equally 57 
likely to be eliminated by the drug and, if they are not eliminated, are all equally likely to 58 
reproduce. This assumption of parasite homogeneity is violated in malaria where a single 59 
infection may harbour individual parasites that become distinctly heterogeneous as they pass 60 
through their development processes within RBCs. Plasmodium falciparum, the most deadly 61 
of the Plasmodium species causing human malaria (20), has a characteristic 48-hour infection 62 
cycle within RBCs. Parasites infect a RBC, establish several membranes and transport 63 
systems to support their subsequent development, digest and detoxify haemoglobin, and 64 
finally initiate deoxyribonucleic acid synthesis to produce the 20 to 40 new parasites that 65 
emerge from the RBC when it ruptures 48 hours after its infection. These developmental 66 
processes are reflected in large changes in the parasite metabolism. Critically, drugs are only 67 
active against those stages that utilise metabolic processes targeted by the drugs so that drug 68 
stage specificity occurs. As an example, many partner drugs in ACTs are believed to target 69 
haem digestion/detoxification and are only effective against trophozoite and schizont stages 70 
(21) when rapid haem digestion is occurring. These partner drugs, however, have long half-71 
lives and are present at active concentrations for several 48-hour cycles after treatment so 72 
parasites pass through all stages in the presence of the drugs and the lack of stage specificity 73 
in the models is not conjectured to be too problematic. Partner drugs in ACTs are combined 74 
with artemisinins. Recent reports on artemisinin resistance potentially evolving in South East 75 
Asia lead to an increased focus on their performance (22-25). It is unknown how artemisinin 76 
resistance may affect clinical impact on therapeutic outcome and reliance on killing effects of 77 
the partner drug in ACTs is imperative. As resistance to these partner drugs starts to evolve, 78 
more pressure is placed on the artemisinin component to ensure that the ACT remains 79 
effective. Clearly, combination drugs with novel components are necessary.Artemisinins 80 
target most of the stages targeted by partner drugs (trophozoites and schizonts) but, 81 
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additionally, they also act against ring stages. They also have marked differences in their 82 
potency against different asexual blood stages (see later discussion of the hyper-sensitive 83 
profile on Figure 1). The other key difference is that artemisinins have relatively short half-84 
lives resulting in their presence at active concentration for only around 4 to 6 hours post 85 
treatment (15). Patients often present for treatment with their infections semi-synchronised 86 
around a mean developmental age of typically around 5 hours (e.g. (14)). In these 87 
circumstances, stage specificity of drug action does have an important impact: If a patient 88 
presents with parasites in stages highly sensitive to artemisinin then the drug will have a large 89 
effect. Conversely, if a patient has parasites that are predominantly in less sensitive stages, 90 
then the artemisinin drug action will be severely compromised.  91 
 92 
Several studies have used pharmacokinetic/pharmacodynamics models that include more than 93 
one parasite stage (26-30). But to our knowledge, there has been no comprehensive 94 
evaluation of the consequences of assuming parasite homogeneity in conventional 95 
continuous-time models.  Heterogeneity cannot be captured by the conventional ODE 96 
approach based on a single compartment for parasite burden in red blood cells, so the 97 
established method to investigate malaria heterogeneity and drug stage specificity is to 98 
replace the continuous-time/ODE approach with a discrete-time model using difference 99 
equations (6). This approach, first described by Hoshen et al. (6) and used by others (14, 15, 100 
31), can be briefly summarised as follows: The model tracks the malaria infection by dividing 101 
the parasite development within RBC into 48 ‘age-bins’, each bin representing 1 hour of 102 
development. These discrete-time models therefore require that each patient’s treatment be 103 
described by 48 equations, each of which has to be updated for each hour of patient follow-up 104 
after treatment (typically up to 63 days (32)). While discrete-time models properly 105 
incorporate the parasite heterogeneity in malaria infections, they are computationally more 106 
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demanding. Furthermore, they have been described in principle (6) but, to date, there appears 107 
to have been no clear investigation of how they should be applied in practice for simulation 108 
of mass malaria treatment used to optimise deployment practices (e.g. alternating deployment 109 
scenarios such as age- or weight-based dosing bands or the impact of poor patient compliance 110 
in tens of thousands of malaria patients (13)).  111 
 112 
The objectives of this study are therefore as follows. Firstly, to investigate the validity of 113 
previous models of antimalarial drug treatment that used the continuous-time approach and 114 
therefore accepted the inherent assumptions of parasite homogeneity (e.g. (5, 7-13, 18, 33)).  115 
Secondly, to quantify how much more accurate and/or less biased discrete-time approaches 116 
are and to identify their appropriate calibration from clinical, field and laboratory studies. 117 
Thirdly, to identify computational shortcuts that improve the accuracy of the continuous-time 118 
approach as the discrete-time approach is relatively slow even using modern supercomputers 119 
so that a faster continuous-time approach may provide rapid analyses appropriate in most 120 
research environments. 121 
 122 
 123 
Methods 124 
 125 
For clarity, the methods are presented in a qualitative, intuitive manner so that the concepts 126 
are, hopefully, accessible to non-modellers. The strategy is to compare and reconcile the 127 
continuous-time and discrete-time approaches by altering the parasite killing rates to match 128 
predicted parasite numbers between the two approaches. For simplicity we only give details 129 
on monotherapy; a discussion of how individual drug calibrations can be combined for 130 
combination therapies can be found elsewhere (12). We assume drugs may have either long 131 
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or short half-lives and either do, or do not, have stage specific killing. We look at all 132 
combinations, giving four drug types in total: 133 
 134 
 A ‘Hypothetical drug 1’ with long half-life and without stage specific killing. 135 
 An ACT ‘Partner drug’ with long half-life and stage specific killing. Typical examples 136 
are mefloquine and lumefantrine (killing in age-bins 18 to 40 inclusive) as well as 137 
piperaquine (killing in age-bins 12 to 36 hours inclusive) (15). 138 
 A ‘Hypothetical drug 2’ with short half-life and without stage specific killing. 139 
 An ‘Artemisinin derivative’ with short half-life and stage specific killing. 140 
The two hypothetical drugs have properties that do not match any existing antimalarial drugs 141 
but are investigated for several reasons. Firstly, to understand and illustrate the general 142 
principles underlying the treatment dynamics. Secondly, novel antimalarial drugs may 143 
eventually be developed that do have these characteristics. Thirdly, the methodology is not 144 
restricted to malaria: in principle, it can be used as a general model for treatment of infectious 145 
agents with stage specificity.  146 
 147 
The continuous-time and discrete-time approaches must be reconciled so that they yield the 148 
same observed killing rates (quantified as the parasite reduction ratio; details are in the 149 
Supplemental Material). All calculations were performed using the statistical software 150 
package R (version 3.1.1) (34). 151 
 152 
 153 
Continuous-time models 154 
 155 
8 
 
The basic method is based on ODEs and is widely applied in simulating antimicrobial drug 156 
treatment (see (35) for a review). For malaria, an ODE is used to track the change in parasite 157 
number according to the amount of drug present, i.e.  158 
 159 
 160 
Equation 1 161 
 162 
where P is the number of parasites in the infection, t is time after treatment, a is the parasite 163 
growth rate (here we assume that each schizont releases ten merozoites that successfully re-164 
invade RBC, giving a = 0.048 per 48 hours), f(C) is the drug parasite killing which depends 165 
on the drug concentration C, and f(I) the killing resulting from the hosts background 166 
immunity. The critical point to note is that P in Equation 1 does not distinguish between 167 
parasite developmental stages (which we term ‘age-bins’, see below) so this standard 168 
methodological approach cannot explicitly account for stage-specific drug action. The 169 
number of parasites at time t after treatment (Pt) is obtained using conventional calculus as 170 
 171 
 172 
Equation 2 173 
 174 
where P0 is the number of parasites at time of treatment, i.e. t = 0 (for details on how this 175 
equation is derived see, for example, the supplemental material to (11)). If the minimum 176 
predicted number is less than 1, then the infection is assumed to be cleared. 177 
 178 
The drug killing function f(C) usually follows the Michaelis-Menton equation, i.e.  179 
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 180 
 181 
Equation 3 182 
 183 
where Ct is the drug concentration at time t (for details see (12)), Vmax is the maximal drug 184 
kill rate per hour or per day, IC50 is the concentration at which 50% of maximal killing occurs 185 
and n is the slope of the dose response curve. Two factors determine the drug killing after 186 
treatment for each drug type: its specific pharmacodynamic profile (Figure 1) and its 187 
Michalis-Menton function. The amount of drug killing plateaus at high concentrations at Vmax 188 
(Equation 3), so a useful simplification (relaxed in Section 4 of the supplemental material) is 189 
to assume the drugs are either present and killing at maximal effect (i.e. Vmax) or are present 190 
at negligible concentrations (i.e. essentially absent). This simple presence-absent assumption 191 
seems appropriate for the partner drugs because their long half-lives mean they are likely to 192 
be present at high concentrations over the period of the stage specific simulations, typically 4 193 
days (= 96 hours). In the case of drugs such as artemisinins with very short half-lives, we 194 
simply define a duration of activity post-treatment (the default value being 6 hours (15)). This 195 
allows the continuous and discrete-time approaches to be matched simply by specifying a 196 
duration of time the drug is present (and killing at maximal effect) post-treatment and 197 
matching Vmax in the continuous-time methodology (Equation 3) to its discrete-time 198 
counterpart maxV′  (see later discussion of Equation 4): this matching will therefore enable the 199 
continuous- and discrete-time models to be directly compared. 200 
 201 
 202 
Discrete-time models  203 
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 204 
Parasites exposed to drug treatment may be in any stage of development within their 48-hour 205 
life-cycle in RBCs and hence differ in their sensibility to the drugs. A conventional method 206 
for dealing with such continuous data is by splitting the data into a computationally-207 
manageable number of discrete ‘bins’. In principle, there can be any number and length of 208 
bins in the discrete-time model but here, following Hoshen et al. (6), we use a simple linear 209 
approach and split the 48-hour parasite development cycle in the RBC into 48 × 1-hour bins. 210 
We will refer to these entities as ‘bins’ or ‘age-bins’ interchangeably depending on context 211 
and need for clarity (note that Hoshen et al. (6) refer to them as ‘boxes’). Patients may 212 
present for drug treatment with parasites in an infinite variety of distributions among these 48 213 
bins. If drugs preferentially act against certain age-bins in the 48-hour cycle, then the 214 
distribution of parasites among the age-bins at time of treatment may have an impact on 215 
subsequent dynamics of parasite clearance. Consequently, each patient must have his/her 216 
distribution of parasites among age-bins defined at the time of treatment. For illustrative 217 
purposes, we identify five ‘paradigm distributions’ (PD1–5) detailed in Section 1 of the 218 
supplemental material of infections that differ in distributions at time of start of treatment. 219 
Briefly these are: 220 
 221 
 PD1: asynchronous and equally distributed over all age-bins 222 
 PD2: mainly in early ring stages with a relatively tight distribution across age-bins 223 
 PD3: mainly in early ring stages with a relatively wide distribution across age-bins 224 
 PD4: mainly in the late ring stages with a relatively tight distribution across age-bins 225 
PD5: mainly in trophozoite stages with a relatively tight distribution across age-bins 226 
 227 
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The first step is to define a ‘pharmacodynamic profile’ for each drug that specifies its parasite 228 
killing for each 1-hour age-bin (Figure 1). We then combine the duration of drug killing after 229 
treatment with the drugs pharmacological profile to identify a value for the maximal drug 230 
killing rate . These calculations are provided in Sections 2 and 3 of the supplemental 231 
material and are summarised in Table 1. The killing in each age-bin, b, at time, t, is then 232 
given as  233 
 234 
       235 
Equation 4 236 
 237 
where Yb is the pharmacodynamic profile so that, in the simplest case, Yb = 1 if the drug does 238 
kill parasites in age-bin b, and Yb = 0 if it does not kill parasites in that age-bin. Zt tracks the 239 
drug concentration post-treatment so that Zt = 1 if the drug is present at time t, and Zt = 0 if 240 
the drug is not present. This allows the proportion of parasites in age-bin b, at time t, that 241 
survive the subsequent hour to be calculated as 242 
 243 
   244 
Equation 5 245 
 246 
which is used in Equation 6 and Equation 7 below to track parasitaemia.  247 
 248 
A two-dimensional matrix, the ‘parasite matrix’ (PM), tracks the total number of parasites in 249 
each bin for each hour post-treatment. The first column (t = 1) of PM holds the initial age-bin 250 
distribution of parasites at time of treatment. The algorithm then simply tracks the number of 251 
maxV′
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b,t
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parasites in the 48 bins after treatment using the standard index methodology dating back to 252 
Hoshen et al. (6) and subsequent (e.g. (14, 15, 17, 31)), i.e. for every age-bin (b) at each time 253 
(t) post-treatment, the algorithm calculates how parasites survive drug treatment and then 254 
moves the survivors on an hour into the next age-bin (i.e. b+1) and into the next time period 255 
post-treatment (i.e. t+1), i.e.  256 
 257 
 258 
Equation 6 259 
 260 
Note that for b = 1 we allow for the production of new parasites at the end of age-bin 48, i.e. 261 
 262 
 263 
Equation 7 264 
 265 
where PMR is the parasite multiplication rate, i.e. the average number of merozoites released 266 
from a schizont that successfully infect new RBC. 267 
 268 
 269 
Reconciling the continuous- and discrete-time approaches 270 
 271 
The calibration requires that equivalent killing rates are identified, i.e. Vmax in Equation 3 and 272 
 in Equation 4, so that parasite numbers obtained from the continuous- and discrete-time 273 
methodology match at the end of each 48-hour cycle (see below). The values of Vmax used in 274 
the continuous- and discrete-time methodologies will be distinguished by using a prime 275 
tb
tbtb
,
,11, PMPM Ψ=++
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maxV′
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symbol (′) for the latter, i.e. . A hat (ˆ) above the Vmax symbol indicates that an 276 
adjustment has been made for the effects of stage specificity and the lack of drug-killing in 277 
non-sensitive stages. A tilde (˜) above the Vmax symbol indicates that an adjustment has been 278 
made for the short half-life of the drug and the times when the drug is absent (and hence not 279 
killing) during the 48 (or 96) hour census period.  280 
 281 
The parasite reduction ratio (PRR) is conventionally measured in the clinic as the number of 282 
(observable) parasites present at the time of treatment divided by their number 48 hours later. 283 
The continuous- and discrete-time models can be calibrated using PRR as a metric of drug 284 
killing by making allowances for the drug’s half-life and the susceptible parasite age-bins. 285 
The basic equations are given in Table 1 which shows how the kill rate calibrations depend 286 
on the amount of drug killing (i.e. PRR), the duration post-treatment that the drug is active, 287 
and parasite growth rate a. In the case of discrete-time modelling it also captures the number 288 
of age-bins in which killing occurs (q). 289 
 290 
A problem arises with the ‘Artemisinin drug’ as it is impossible to match  and  291 
such that continuous- and discrete-time models give identical parasites numbers at the end of 292 
each 48-hour cycle (see later). This mismatch arises because the age-bin distribution at time 293 
of treatment has a large effect on subsequent dynamics so  and  had to be matched 294 
using the parasite reduction ratio predicted to occur over 96 hours (PRR96), i.e. the number of 295 
parasites present at the time of treatment divided by the number 96 hours later. The 296 
calculations required for this are given in Section 3 of the supplemental material. 297 
 298 
 299 
maxV ′
48 max,
~ˆV 48 max,~ˆV ′
max
~ˆV max~ˆV ′
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Parameterisation of models 300 
 301 
We used published results where available and attempted to identify plausible values 302 
otherwise. In all cases we use, rather than endorse these calibrations so this approach makes it 303 
straightforward for readers to calibrate the simulations according to their own local clinical 304 
and epidemiology settings.  305 
 306 
 307 
Simulating artemisinin treatment in patient populations using continuous-time models 308 
 309 
The methods described above allowed us to calibrate the continuous-time method such that it 310 
captures the effects of stage specificity. The obvious practical application of the new 311 
methodology is to simulate the deployment of ACTs for mass treatment of patients and to 312 
assess the impact of stage specificity on predicted population-wide drug effectiveness; the 313 
latter has been missing from previous analyses. This source of variation has not been 314 
incorporated into previous simulations of ACT treatment (e.g. (11, 12)) so we need to 315 
incorporate and assess its likely impact on the predicted treatment outcomes. We do this by 316 
re-running our previous simulations of artemether-lumefantrine (AM-LF) and artesunate-317 
mefloquine (AS-MQ) treatment (12). The process for doing so is described in Section 3 in the 318 
supplemental material. In brief, we ran the model for multiple patients to determine the 319 
population PRR96 and used this to obtain a continuous-time approximation for 96 max,
~ˆV ′ . This 320 
new estimate of 96 max,
~ˆV ′ , and its associated inter-patient variability, was then incorporated into 321 
mass simulations of ACTs to account for the stage-specific effects of the artemisinin 322 
component. 323 
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 324 
 325 
Results  326 
 327 
Continuous-time and discrete-time models for different types of drugs 328 
 329 
The parasite numbers predicted by the continuous-time and discrete-time models for a drug 330 
with a long half-life that kills all parasite stages (‘Hypothetical drug 1’) are compared in 331 
Figure 2A. The lack of stage specific killing means that variation around the continuous-time 332 
approximation is due solely to differences caused by parasites reproducing at the end of their 333 
48 hour cycle. Infections that were initially in late age-bins, such as PD5, will rupture and 334 
produce new parasites (merozoites) early in the 48-hour census period so parasite numbers 335 
will remain higher than the continuous-time prediction over most of the census period. Those 336 
infections that were initially in early age-bins of the cycle, such as PD2, release merozoites 337 
late in the 48-hour census period so their numbers will usually lie below the continuous-time 338 
approximation. As expected, all predicted numbers converge to the same value at the end of 339 
each 48-hour census period. 340 
 341 
Figure 2B compares parasite numbers predicted by the continuous-time and discrete-time 342 
models for a drug with a long half-life that has stage specificity. The example shown in 343 
Figure 2B is for the ‘lumefantrine’ pharmacodynamic profile but similar results were 344 
obtained for the ‘piperaquine’ profile (Figure S3). The major difference between Figure 2A 345 
and Figure 2B is that in Figure 2B the effect of stage specificity is added to the effect of 346 
initial age-bin distributions, and variation around the continuous-time approximation is 347 
substantially increased compared to Figure 2A. The patterns of variation can be understood as 348 
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the interaction between these two effects. In an infection with parasites that are 349 
predominantly in late age-bins at the start of treatment (e.g. PD5) some parasites are killed, 350 
but many parasites do survive to rupture and release merozoites that are then unaffected by 351 
the drug for the next 18 hours (Figure 1). Consequently, parasite numbers in an infection with 352 
PD5 stay well above the continuous-time approximation for the whole census cycle. When 353 
parasites are mainly in early bins (e.g. PD2) at time of treatment, they are not affected by the 354 
drug and their total number is initially above the approximation until the time point when the 355 
parasites start to enter the sensitive bins (at 18 hours) where intense killing brings their total 356 
number down below the number predicted by the continuous-time model. Parasites initially 357 
distributed according to PD4 suffer badly from both effects as their mean age is 20.5 hours, 358 
i.e. parasites are initially killed very effectively by the drug and only when significant rupture 359 
and release of merozoites occurs around 20 hours post-treatment does their number start to 360 
re-converge towards that predicted by the continuous-time model.  361 
 362 
Figures 2C and 2D compare parasite numbers predicted by the continuous-time and discrete-363 
time models for a drug with a short half-life and that kills all stages (i.e. ‘Hypothetical drug 364 
2’). The major difference between Figure 2A (‘Hypothetical drug 1’) and Figures 2C and 2D 365 
is that ‘Hypothetical drug 2’ persists for only a relatively brief period after treatment. The 366 
short half-life means that such drugs would probably be given repeatedly so the dynamics are 367 
shown both for a single dose (Figure 2C) and for three repeated doses (Figure 2D). Parasite 368 
numbers initially fall rapidly and their subsequent recovery is then driven by the same 369 
dynamics as longer half-life drugs without stage specificity (Figure 2A), i.e. parasite numbers 370 
in PDs with high mean (e.g. PD5) multiply sooner in the 48-hour census period and are thus 371 
usually higher than predicted by continuous-time models, while those in PDs that have a low 372 
mean (e.g. PD2) multiply later in the 48-hour census and are thus usually lower than 373 
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predicted. Critically, all PDs and the continuous-time approximation re-converge at the end 374 
of each 48-hour cycle.  375 
 376 
Figure 3 compares the continuous-time and discrete-time models for a drug with a short half-377 
life with the stage specific characteristics of the artemisinin class of drugs. It is extremely 378 
difficult to capture the post-treatment dynamics by a single continuous-time equation because 379 
of the impact of an infection’s age-bin distribution at time of treatment. Figure 3 used the 380 
continuous-time approximation with a  calibrated from PD1 (using Equation S16). 381 
Note that, for instance, PD4 is very poorly captured by this approximation and, importantly, 382 
the parasite numbers do not re-converge every cycle (Figure 3A, in contrast to Figure 2A, B, 383 
C and D) so the mismatch will be perpetuated over subsequent cycles (Figure 3B). This 384 
makes it necessary to use a different continuous-time calibration for each of the five 385 
paradigm distributions by using the approach leading to Equation S26 in Section 3 of the 386 
supplemental material (Figure 4). Slight differences between the discrete- and continuous-387 
times methods for each paradigm distribution do occur but, importantly, the continuous- and 388 
discrete-time methods always re-converge after 96 hours (Figure 4) irrespective of the age-389 
bin distribution at time of treatment (the panels on Figure 4 illustrate five very different 390 
starting age-bin distributions) and every 48 hours thereafter as shown on Figure S4. The first 391 
convergence occurs after 96 hours because parasite killing of artemisinins has to be calibrated 392 
over a 96-hour period (rather than the 48-hour period for the other examples). The 393 
convergence in subsequent 48-hour census periods is due to the match in PMR. 394 
 395 
 396 
Mass simulations of treatment 397 
 398 
48 max,
~ˆV
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We replicated our recent mass simulation of AM-LF and AS-MQ treatment (12) to include 399 
stage specific drug action of artemisinins by allowing an additional two-fold variability 400 
around artemisinin   (Equation S28). Its inclusion made very little difference to the 401 
results (Figures S5 and S6 and Table S2): Cure rates using our original mean  of 27.6 402 
per day changed from 84.74% to 84.13% for AS-MQ and from 92.29% to 91.76% for AM-403 
LF. There was similarly a very small effect of stage specificity when we reduced artemisinin 404 
to 14.6 per day (the reasons for using this lower artemisinin are explained 405 
below.) 406 
 407 
 408 
Discussion 409 
 410 
Comparison of output from continuous-time and discrete-time models for different 411 
types of drugs 412 
 413 
The calibrations presented in the supplemental material and summarised in Table 1 enabled 414 
the continuous- and discrete-time methods to be calibrated in an equivalent manner. This 415 
allowed us to investigate the extent to which the continuous-time approximation captures the 416 
more biologically-realistic discrete-time models.   417 
 418 
Initial investigations used the simplest example, ‘Hypothetical drug 1’ which is assumed to 419 
have a long half-life and kill all age-bins. This isolated the effect of replicating at the end of 420 
the RBC life-cycle as being the only difference between the continuous- and discrete-time 421 
approaches. Results suggest that replication solely at the end of the 48-hour cycle introduced 422 
96 max,
~ˆV
96 max,
~ˆV
96 max,
~ˆV 96 max,~ˆV
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only a small amount of variation around the treatment dynamics predicted by a continuous-423 
time approach (Figure 2A). The discrepancy between predicted and actual numbers is small, 424 
about plus/minus half a log10 unit, and importantly is constant over subsequent cycles. The 425 
latter point is important because the infection is deemed to have been cleared if the expected 426 
number of parasites falls below 1, and variation around predicted parasite number at that 427 
point is relatively low suggesting the continuous-time approximation for therapeutic outcome 428 
(i.e. cure/fail) should be applicable for this type of drug. Our (subjective) interpretation of 429 
these results is that the assumption of continuous replication is unlikely to have a significant 430 
impact on the results from studies where drugs lack stage specific activity.  431 
 432 
The next step was to add stage specific drug action to a long half-life drug (i.e. the ACT 433 
partner drugs). This combined the impact of stage specificity with that of replication 434 
occurring only at the end of the 48-hour life-cycle. The results are illustrated on Figure 2B. 435 
As might be expected, stage specificity introduces considerably more variation around the 436 
continuous-time approximation. These are important examples as they characterise an 437 
antimalarial ‘partner’ drug whose treatment has been previously examined using a 438 
continuous-time approach both by us (e.g. (11-13)) and by others (e.g. (7, 10, 33)). An 439 
important, and long overdue, question is the extent to which the continuous-time approach 440 
truly predicts the drug post-treatment parasite dynamics. We would argue, again subjectively 441 
that the approximation is good. The key factor is that the variation disappears every 48 hours 442 
and that it scales with parasite number such that maximum deviation is around two log10 443 
units, i.e. a factor of 100. The continuous-time approach defines the infection as ‘cured’ when 444 
the predicted number of parasites falls below 1. Figure 2B and Figure S3 suggest this may 445 
arise if the predicted number was within two log10 units ether side, i.e. from 0.01 to 100. It 446 
seems intuitively likely that discrepancies of this relatively small magnitude would rarely 447 
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occur and, consequently, that continuous-time simulations would be accurate. This argument 448 
also assumes the worst-case scenario, i.e. that the drug instantaneously disappears at exactly 449 
the point when the discrepancy is maximal. In reality, the smooth transition from maximum 450 
killing to ineffective concentrations would likely help smooth out the discrepancies.   451 
 452 
The third drug class investigated were drugs with a short half-life and without stage specific 453 
killing (i.e. ‘Hypothetical drug 2’). The short half-life means that parasite numbers initially 454 
fall rapidly but recovered once the drug is not present anymore (Figure 2C and D). The 455 
change in parasite number is driven by the same dynamics as longer half-life drugs without 456 
stage specificity (Figure 2A) and the continuous-time approximation re-converge at the end 457 
of each 48-hour cycle. This re-convergence, plus relatively small deviations between the 458 
model types suggest that, should such an antimalarial be discovered and deployed, that the 459 
continuous-time methodology would be an appropriate simulation method. 460 
 461 
Finally, the effects of short half-life, stage specific killing and replication only at the end of 462 
the 48-hour cycle was investigated (i.e. the artemisinin derivatives). The implications are 463 
much more serious for the continuous-time approach. Figure 3 shows the dynamics of 464 
artemisinin treatment: Deviation from the continuous-time approximation is larger, e.g. 465 
around 3 log10 units or 103-fold in the case of PD4 and, critically, the deviation does not 466 
periodically disappear (as it does every 48 hours for partner drugs, see Figure 2B and Figure 467 
S3). Consequently, deviations persist over time and will plausibly have an impact on 468 
predicted therapeutic outcome. In our opinion, this is an unacceptable level of divergence and 469 
we conclude that artemisinin treatment cannot be adequately modelled in the same way as the 470 
other drugs because the initial age-bin distribution at time of treatment has such a large effect 471 
on the PRR. 472 
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 473 
Figure 4 shows that a continuous-time approximation calibrated for initial bin distribution 474 
accurately tracks killing over the 2 × 48-hour parasite life-cycles that artemisinins are present, 475 
and supports our assertion that employing infection-specific continuous-time kill rates  476 
(Figure 4, Figures S7) can capture the variation introduced into post-treatment dynamics by 477 
patients’ differing age-bin distributions at time of treatment. The essence of our argument is 478 
that the effects of differing bin distribution at time of treatment can be incorporated simply by 479 
inflating the variation in a drug’s maximal kill rates.  480 
 481 
 482 
Estimates of artemisinin kill rates  483 
 484 
The inclusion of stage specificity into our recent mass simulation of AM-LF and AS-MQ 485 
treatment [12] made very little difference to the results (Figures S5 and S6 and Table S2). 486 
There was similarly a very small effect of stage specificity when we reduced artemisinin 487 
 to 14.6 per day (the reasons for investigating this reduced are explained below). The 488 
analyses show that artemisinin kill rates (  ~0.6 per hour; Table 2, Figure S7) are much 489 
lower (by a factor of around two) than estimated in our previous studies which used values of 490 
27.6 per day (12, 13), equivalent to 1.15 per hour (i.e. 27.6/24). There appear to be two 491 
underlying reasons for this. Firstly, the use of PRR to calibrate the killing, secondly the 492 
extrapolation of PRR to overall kill rates; each will be discussed in turn.  493 
 494 
Previous simulations of artemisinin treatment were calibrated using the observed PRR (i.e. 495 
the reduction in circulating and sequestered parasites) of around 104 reported in the literature 496 
96 max,
~ˆV
96 max,
~ˆV
96 max,
~ˆV
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and defined as the reduction in the number of parasites observed in the peripheral blood by 497 
microscopy. This is potentially misleading because they do not capture changes in the 498 
number of sequestered parasites. Our simulations allow us to calculate both “apparent” and 499 
true” PRR and suggest that apparent PRR48 is substantially larger than the true PRR48 (Table 500 
2). The effect of short pulses of stage specific artemisinin killing on observable, circulating 501 
parasites (age-bins up to 14) and sequestered parasites (age-bins 15 and above), and hence on 502 
observed PRR, varies greatly depending on the initial age-bin distribution of the parasites 503 
(Figure S10 and Figure S11).  504 
 505 
The second factor behind the discrepancy in artemisinin maximal kill rates arises because, in 506 
vivo, the PRR is typically measured over 48 hours. This omits the impact of the final dose at 507 
time 48 and it is assumed that the results for the first two doses (which determine PRR) may 508 
be extrapolated for the third dose. However, a dose of artemisinin given 48 hours after the 509 
first dose will affect exactly the same age-bins already targeted by the first dose. 510 
Consequently, that third dose is likely to have much less impact than the first two doses. 511 
Calibration against PRR48 only captures the effects of the first two doses and will thus 512 
overestimate the impact of the third dose. Calibration against PRR96, as done here, does 513 
incorporate the reduced impact of the third dose and so the estimated artemisinin kill rates 514 
 are further reduced.  515 
 516 
As may be expected, this reduction in artemisinin kill rate may have a significant impact on 517 
simulated drug effectiveness. Our mass simulations based on previous work (12) show that 518 
reducing  from 27.6 to 14.4 per day (i.e. 24 × 0.6 = 14.4 to convert hourly to daily kill 519 
rates) roughly doubled the number of predicted treatment failures (Table S2).  520 
96 max,
~ˆV
96 max,
~ˆV
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 521 
 522 
Impact of stage-specificity on mass simulations of ACT treatment 523 
 524 
Incorporating the two-fold variation caused by age-bin distributions again had a negligible 525 
effect as seen with the higher kill rate. The underlying reason appears to be that this two-fold 526 
variation adds very little to the natural variation in parasite sensitivity to the drug’s  527 
whose coefficient of variation (CV) was assumed to be 0.3 (12) (this is shown in Figures S5 528 
and S6). Recall we first sampled  from a normal distribution to reflect the natural 529 
variation among parasites in their  values; the resulting simulated distributions are 530 
shown as rows A and C on Figures S5 and S6. We then re-sampled  from a two-fold 531 
range around this selected value to allow for differences in infections’ age-bin distribution at 532 
time of treatment (cf Figure S7); the distribution of these re-sampled values are shown in 533 
rows B and D of Figures S5 and S6. Note, the variation increases slightly as this two-fold 534 
effect is included and that the distribution becomes slightly more right-skewed. The skew 535 
arises because the uniform distributions are scaled against the selected value of  536 
(Equation S28) so high values (at the right-hand side of the distribution) have higher 537 
additional variation that tends to slightly skew the distribution at this side. The important 538 
point is that the variation in  values increases only marginally in rows A and C versus 539 
rows B and D on Figures S5 and S6. In effect, it appears that the additional variation 540 
introduced by artemisinin stage-specific killing and its short half-life is largely incorporated 541 
96 max,
~ˆV
96 max,
~ˆV
96 max,
~ˆV
96 max,
~ˆV
96 max,
~ˆV
96 max,
~ˆV
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into the natural background version in  so that the impact on cure rates, at least in our 542 
examples, is negligible (Table S2).  543 
 544 
Variation in age-bin distributions at time of treatment therefore appear to have little impact in 545 
our simulations but there is no guarantee that this will be the case in all studies and it is good 546 
practice to incorporate this effect if possible. The results for SPP2 and SPP3 shown in Figure 547 
S7 suggest a general rule of thumb: In the absence of any better information, the natural 548 
variation in artemisinin kill rate  should be augmented two-fold to incorporate age-bin 549 
variation in patients at time of treatment. Our mass simulation, however, showed that adding 550 
this variability to an individual’s drug killing rate, , did not affect predicted cure rates 551 
(Table S2). The natural variation around the mean of  is so large (i.e. CV = 0.3) that the 552 
distribution of patients’ barely changes when the correction for stage specificity is 553 
added (Figures S5 and S6). 554 
 555 
Impact of adherence 556 
 557 
The simulations assumed full patient adherence to 24-hour dosing intervals. However, in 558 
practice patients may miss a dose, delay a dose by several hours or finish treatment early. We 559 
investigated adherence in a previous publication (13) but assumed artemisinin doses were all 560 
equally effective. In reality, the impact of dose timing and the fact that the third dose of the 561 
artemisinin appears to have less impact suggests that a more nuanced approach could be used 562 
to investigate the impact of poor adherence. This could be incorporated in the same way as 563 
the effects of initial bin distribution, i.e. simulate a range of initial age-bin distributions with a 564 
96 max,
~ˆV
96 max,
~ˆV
96 max,
~ˆV
96 max,
~ˆV
96 max,
~ˆV
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range of adherence patterns, compute PRR96 for each patient within the population and use 565 
this to generate the distribution of  analogous to Figure S7 that also incorporates the 566 
effect of adherence patterns. 567 
 568 
 569 
Conclusions 570 
 571 
The potential impact of age-bin distribution on drug treatment may be obvious in retrospect. 572 
In fact, it is not a new idea but seems to have been lost in the artemisinin era (just when it was 573 
most relevant). The stage specific action of antimalarials has been investigated since the early 574 
1980s (21, 36, 37) so it is therefore not surprising, that chronotherapy for malaria, i.e. the 575 
science of the timing of drug application so as to achieve optimal therapeutic success for the 576 
treatment of disease, is an old idea (38). Following administration of an ACT, the partner 577 
drug is present in the patient’s blood at concentrations above the minimal inhibitory 578 
concentration (MIC) over several parasite life-cycles of 48 hours (39) so it is therefore 579 
unlikely that the timing of partner drug application would affect treatment outcome (Figure 580 
2B). However, the artemisinins are present in the blood at concentrations above the MIC only 581 
during a very short period of time, i.e. 4-6 hours (15), and chronotherapeutic considerations 582 
seem justified (Figure 3). It is difficult to envisage exactly how this would be achieved in 583 
practice (it would be unethical to delay treatment) but more frequent dosing with artemisinins 584 
as occurs in the twice-per-day regimen of AM-LF, may help in this respect and deserves 585 
further investigation. As mentioned before, the WHO recently recommended the use of 586 
mathematical models on antimalarial chemotherapy for a better understanding of drug 587 
resistance and its management (40). The advantage of mathematical models is that they can 588 
96 max,
~ˆV
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overcome some of the experimental, ethical or logistic issues associated with in vitro 589 
experiments or clinical trials on stage specificity of antimalarials.  590 
 591 
The discrete-time methodology will remain the “gold-standard” simulation method but we 592 
believe the continuous-time methods will continue to be used in the foreseeable future 593 
because they offer a substantial increase in computational speed with, as we show in this 594 
manuscript, no compromise in the validity of their results. The increase in speed arises 595 
because the discrete-time models track 48 parasite developmental “bins” each of which has to 596 
be updated every hour (i.e. 24 times per day). In contrast, the continuous-time method tracks 597 
only the total number of parasites and, for most malaria drugs, is only updated daily. The 598 
ratio of computations (and hence basic speed) is therefore 1:(48 × 24), making the 599 
continuous-time approach >1,000-fold faster (with the exception of artemether-lumefantrine 600 
which is administered twice-daily, in which case the computational advantage halves to 601 
~500-fold). Moreover, this simple calculation ignores the computational opportunity of time-602 
saving by using calculus to project forward after the final dose in the continuous-time 603 
methods (see Appendix of (7)). In crude terms, this means the continuous method can run 604 
overnight (half day) what the discrete time method would take around a year to achieve.  605 
These simulations are highly suitable for parallel or batch processing over multiple computer 606 
cores, but no matter how many batches or cores are used, the 500–1,000× speed advantage 607 
still remains. Computational speed is important because malaria simulations have grown 608 
increasingly complex to take advantage of increased computational power, and large-scale 609 
modelling is envisaged to play a significant role in optimising malaria control and elimination 610 
programmes (3). For example, we have embedded a continuous-time methodology of drug 611 
treatment into the large-scale OpenMalaria micro-simulation of malaria epidemiology (e.g. 612 
(41, 42)). Testing various permutations of malaria epidemiology, transmission and clinical 613 
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practices typically takes 2–3 weeks to complete, so computational speed does remain a 614 
priority in such situations. Similarly, investigating the large number of different permutations 615 
of age- and weight-banding patterns under a variety of target dose ranges (in mg/kg, see (13)) 616 
is computational intensive and a 500–1,000× times increase in speed is extremely valuable in 617 
this context. What this paper has achieved is to validate a methodology, with particular 618 
relevance for artemisinins, which offers an extremely large increase in computational speed, 619 
and which confirms the validity of previous analyses published using the continuous-time 620 
approach. 621 
 622 
 623 
This piece of work is overdue and ideally would have been performed before undertaking the 624 
mass simulations of malaria treatment that ignored stage specificity (we consider ourselves as 625 
guilty as anyone in this respect). It is interesting that the sizes of impact of the three features 626 
of stage specificity are in reverse-order of that anticipated at the start of this work. Stage 627 
specificity of artemisinin killing does inflate the variance associated with treatment but is 628 
largely lost in the context of ‘natural’ parasite variation in drug sensitivity (Figures S5 and 629 
S6) and had little impact on our predicted ACT effectiveness (Table S2). Stage specificity 630 
and the long half-life of partner drugs do have some impact on the minimum number of 631 
predicted parasites, and hence predicted therapeutic outcome, but the likely size of this effect 632 
seemed small and can be monitored by recording the minimum number of predicted parasites 633 
in each patient (Table S2). The largest effect arose from the combination of sequestration and 634 
a reduced impact of the third dose of artemisinin. This lead to estimated artemisinin killing 635 
being around half that obtained previously from a cruder interpretation of PRR over 48 hours 636 
(i.e. assuming that all parasites are observable) and had a large impact of predicted cure rates 637 
(Table S2). We would however stress these are initial conclusions based on a re-analysis of 638 
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some of our previous simulations of ACT treatment with the specific 639 
pharmacokinetic/pharmacodynamic calibrations described above. Our explicit objective here 640 
was to develop and present the computational techniques necessary to bring stage specificity 641 
into mass simulations of drug treatment regimens. In order to maintain a publication of 642 
manageable size, we chose not to undertake a systematic investigation of parameter space. 643 
We have attempted to be as transparent and flexible as possible so that users can easily 644 
calibrate and apply the techniques to their own particular settings and simulations. We 645 
strongly recommend that stage specificity be explicitly considered in simulations of malaria 646 
treatment and look forward to the results obtained from other studies. 647 
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Table 1. Drug killing rates for the continuous-time and discrete-time models. These are the equations required to convert the discrete-time 793 
model to its continuous-time equivalent for a single patient, i.e. to match maximal parasite kill rate (Vmax in Equation 3) in the instantaneous 794 
model to its equivalent  in the discrete-time model (Equation 4), the latter being denoted by the prime (′) symbol. The hat (ˆ) or tilde (˜) 795 
above the Vmax symbol indicate whether adjustment has been made for the effects of stage specificity and/or short half-life respectively to 796 
compensate for the lack of drug-killing in non-sensitive stages and times when the drug is not present during the 48 (or 96) hour census period.  797 
Drug Half-life Stage specificity Continuous-time model Discrete-time model 
‘Hypothetical drug 1’ Long No 
  
‘Partner drug’ Long Yes 
   
‘Hypothetical drug 2’ Short No 
  
‘Artemisinin derivative’ 
PRR48 calibration 
Short Yes 
  
‘Artemisinin derivative’ 
PRR96 calibration 
Short Yes 
 
Obtained by iteration 
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a: instantaneous parasite growth rate over the 48-hour parasites red blood cell (RBC) cycle; PRR48/PRR96: reduction in parasite number over 48 798 
or 96 hours (i.e. one or two parasite RBC cycles) following drug treatment, the value is different for each drug but identical for both models 799 
when used for the same drug; q: number of one-hour bins during which killing occurs; ta: duration of drug action after each dose. 800 
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Table 2. The impact of age-bin distribution at time of treatment on continuous-time 801 
artemisinin kill rates. True parasite reduction ration (PRR) is the reduction in total number 802 
of parasites and apparent PRR is the reduction in observable (i.e. non-sequestered and thus 803 
circulating) number of parasite per 48 or 96 hours. A discrete-time artemisinin kill rate  804 
(  = 1.164) was obtained that gave an apparent parasite reduction ratio PRR48 of ~104 805 
(actually 10,054) using the following assumptions: (i) uniform age-bin distribution, (ii) three 806 
doses of an artemisinin are given at times 0, 24 and 48 hours (although, obviously, only the 807 
first two doses contribute to the PRR48) and persist for 6 hours following each dose, (iii) iso-808 
sensitive pharmacodynamic profile (14), (iv) parasites immediately disappear from the 809 
circulation at age-bin 14 hours. See supplemental material for methodological detail and 810 
Table S1 for more results. The continuous-time equivalent artemisinin drug kill rate ( ) 811 
is calculated from true PRR96 using Equation S26. Note that the discrete-time kill rates are 812 
identical for each row (  = 1.164) so that the variation in continuous-time kill rate 813 
 is caused solely by the differences in age-bin distribution at time of treatment. The 814 
dynamics of treatment are shown on Figure 4. 815 
Distribution 
(mean, SD) 
True 
PRR48 
Apparent 
PRR48 
True 
PRR96 
Apparent 
PRR96 
Kill rate 
 
PD1 (uniform) 541 10,054 125 14,268 0.52408 
PD2 (10.5, 5) 2,032 20,024 416 34,692 0.59085 
PD3 (10.5, 10) 518 11,873 112 17,533 0.51776 
PD4 (20.5, 5) 324 84,293 34,822 8,770,475 0.83684 
PD5 (35.5, 5) 1,889 3,069 397 3,145 0.58822 
 816 
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Figure 1. The pharmacodynamic profiles of antimalarial drugs used in the discrete-time 817 
methodology. The profiles describe the fraction of parasites killed per hour by the drug for 818 
each of the 48-hour age-bins (i.e. 1-Ψb,t from Equation 5). Calibration are based on an 819 
asynchronous, ‘uniform’ parasite infection which results in a PRR48 = 103 (lumefantrine, 820 
mefloquine and piperaquine) or PRR48 = 104 (artemisinins). We investigated two sensitivity 821 
profiles to artemisinins. The “iso-sensitive” profile assumes all parasite stages are equally 822 
sensitive to artemisinin: this is essentially the same profile as for partner drugs but with a 823 
wider range of stages being killed. The other “hyper-sensitive” profile assumes differential 824 
artemisinin killing between the stages. This seems intuitively plausible because drug 825 
sensitivity presumably depends on the metabolic processes taking place in each stage of 826 
development and also reflects recent findings that P. falciparum appears far more sensitive to 827 
artemisinins in the early ring stages than in later stages (43). 828 
Figure 2. Changes in parasite numbers following treatment. The graph shows the number 829 
of parasites over time post treatment. Parasites present at time of treatment were distributed 830 
among age-bins according to paradigm distributions (PD) 1–5 described in Section 1 of the 831 
supplemental material. Note that the number of parasites is the true number, i.e. circulating 832 
plus sequestered, plus one (it is conventional to plot parasites + 1 when using a log scale 833 
because log(0) is undefined). (A) Drug with long half-life and equal killing in all age-bins 834 
(e.g. ‘Hypothetical drug 1’). This was produced using the pharmacodynamic profile of 835 
‘hypothetical drug 1’. The discrete-time model used drug killing rate  = 0.1919 and Yb = 836 
1 for age-bins 1 to 48 and the continuous-time model used drug killing rate = 0.1919. (B) 837 
Drug with long half-life and stage specific killing (e.g. lumefantrine). This was produced 838 
using the pharmacodynamic profile of drug ‘lumefantrine’. The discrete-time model used 839 
drug killing rate = 0.4005, Yb = 1 for age-bins 18 to 40 inclusive and Yb = 0 for age-bins 840 
maxV′
maxV
maxVˆ′
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0 to 17 and 41 to 48 inclusive and the continuous-time model used drug killing rate  = 841 
0.1919. (C) Drug with short half-life and equal killing in all age-bins (i.e. ‘Hypothetical drug 842 
2’) given as a single dose and assuming that the drug is present and acting at maximal killing 843 
for 6 hours post-treatment (15). The discrete-time model used drug killing rate = 0.1919, 844 
Yb = 1 for age-bins 1 to 48 and Zb = 1 for the 6 hours the drug was present and the 845 
continuous-time model used drug killing rate  = 1.919.single dose administered at time 0 846 
hours (green arrow). (D) As for (C) but with three doses administered at times 0, 24 and 48 847 
hours (green arrows). 848 
Figure 3. Changes in parasite numbers following treatment by a drug with short half-849 
life and stage specific killing (e.g. ‘Artemisinin derivative’). This was produced using the 850 
iso-sensitive pharmacodynamic profile of the artemisinins (see Figure 1) and assuming that 851 
the drug is present and acting at maximal killing for 6 hours after each dose (15). 852 
Artemisinins are simulated as a monotherapy for clarity. They can later be combined to 853 
simulate combination therapies (12) so parasite numbers start to increase shortly after the 854 
final dose. Parasites present at time of treatment were distributed among age-bins according 855 
to paradigm distributions (PD) 1–5 described in Section 1 of the supplemental material. The 856 
continuous-time model used a single drug killing rate  = 0.52408, i.e. the one 857 
calibrated to give a PRR48 = 104 for a uniform distribution (Table 2). Note that the number of 858 
parasites is the true number, i.e. circulating plus sequestered, plus one (it is conventional to 859 
plot parasites + 1 when using a log scale because log(0) is undefined). (A) shows the 860 
dynamics in detail up to 96 hours and (B) shows how the parasite numbers remain separate 861 
thereafter. 862 
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Figure 4. Changes in parasite numbers following treatment by a drug with short half-864 
life and stage specific killing with continuous-time approximation corrected for 865 
patients’ differing bin distributions at time of treatment. This was produced using the iso-866 
sensitive pharmacodynamic profile of the artemisinins (see Figure 1) and assuming that the 867 
drug is present and acting at maximal killing for 6 hours after each dose (15). Parasites 868 
present at time of treatment were distributed among age-bins according to paradigm 869 
distributions (PD) 1–5 described in the text. Unlike Figure 3 the discrete-time analysis of 870 
stage specificity and its continuous-time approximation re-converge at 96 hours for each 871 
paradigm distribution. The artemisinins have disappeared from the circulation by this time so 872 
the continuous-time approximation does capture the total amount of artemisinin drug killing. 873 
These examples use the continuous-time kill rate, , appropriate for each distribution 874 
(Table 2), i.e. (A) PD1:  = 0.524; (B) PD2:  = 0.591; (C) PD3:  = 0.518; 875 
(D) PD4:  = 0.837; (E) PD5:  = 0.588. Note that the number of parasites is the 876 
true number, i.e. circulating plus sequestered, plus one (it is conventional to plot parasites + 1 877 
when using a log scale because log(0) is undefined). 878 
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